Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C11H13N5O2 |
| Molecular Weight | 247.2532 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC2=C(N=CN2[C@@H]3C[C@H](CO)C=C3)C(=O)N1
InChI
InChIKey=XSSYCIGJYCVRRK-RQJHMYQMSA-N
InChI=1S/C11H13N5O2/c12-11-14-9-8(10(18)15-11)13-5-16(9)7-2-1-6(3-7)4-17/h1-2,5-7,17H,3-4H2,(H3,12,14,15,18)/t6-,7+/m1/s1
| Molecular Formula | C11H13N5O2 |
| Molecular Weight | 247.2532 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Carbovir is a nucleoside reverse transcriptase inhibitor analog of guanosine. Carbovir decreases HIV viral loads, retards or prevents the damage to the immune system, and reduces the risk of developing AIDS. Carbovir Triphosphate belongs to the class of organic compounds known as nucleoside and nucleotide analogues. These are analogues of nucleosides and nucleotides. Carbovir interferes with the enzyme HIV uses to manufacture new viral particles within an infected cell, and is primarily metabolized to the 5'-triphosphate of Carbovir (CBV-TP) to concentrations sufficient to inhibit HIV reverse transcriptase.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro. | 1988 Oct 31 |
|
| Synthesis and anti-HIV activity of carbocyclic 2',3'-didehydro-2',3'-dideoxy 2,6-disubstituted purine nucleosides. | 1990 Jan |
|
| Resolution of racemic carbovir and selective inhibition of human immunodeficiency virus by the (-) enantiomer. | 1990 May 16 |
|
| Carbovir: the (-) enantiomer is a potent and selective antiviral agent against human immunodeficiency virus in vitro. | 1991 Feb |
|
| Evaluation of synergy between carbovir and 3'-azido-2',3'-deoxythymidine for inhibition of human immunodeficiency virus type 1. | 1993 Jan |
|
| Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89. | 1997 May |
|
| 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity. | 1997 May |
|
| Correlation of anti-HIV activity with structure: use of electrostatic potential and conformational analysis. | 1999 Jul 19 |
|
| Direct analysis of a polar pharmaceutical compound in plasma using ultra-high flow rate liquid chromatography/mass spectrometry with a mixed-mode column. | 2001 |
|
| Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. | 2001 Nov 2 |
|
| Antiviral activity of cyclosaligenyl prodrugs of acyclovir, carbovir and abacavir. | 2001 Sep |
|
| Pd asymmetric allylic alkylation (AAA). A powerful synthetic tool. | 2002 Jan |
|
| Novel use of a guanosine prodrug approach to convert 2',3'-didehydro-2',3'-dideoxyguanosine into a viable antiviral agent. | 2002 Mar |
|
| Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens. | 2005 Aug 1 |
|
| Simultaneous analysis of several antiretroviral nucleosides in rat-plasma by high-performance liquid chromatography with UV using acetic acid/hydroxylamine buffer Test of this new volatile medium-pH for HPLC-ESI-MS/MS. | 2005 Jul 25 |
|
| N6-methyl-AMP aminohydrolase activates N6-substituted purine acyclic nucleoside phosphonates. | 2006 Apr 28 |
|
| Mitochondrial toxicity of tenofovir, emtricitabine and abacavir alone and in combination with additional nucleoside reverse transcriptase inhibitors. | 2007 |
|
| Interaction of 2'-deoxyguanosine triphosphate analogue inhibitors of HIV reverse transcriptase with human mitochondrial DNA polymerase gamma. | 2007 |
|
| Synthesis of novel 2'-methyl carbovir analogues as potent antiviral agents. | 2007 Feb |
|
| Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages. | 2013 Mar |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 07:27:57 GMT 2023
by
admin
on
Sat Dec 16 07:27:57 GMT 2023
|
| Record UNII |
05469V2RW8
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C97452
Created by
admin on Sat Dec 16 07:27:57 GMT 2023 , Edited by admin on Sat Dec 16 07:27:57 GMT 2023
|
||
|
FDA ORPHAN DRUG |
41189
Created by
admin on Sat Dec 16 07:27:57 GMT 2023 , Edited by admin on Sat Dec 16 07:27:57 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
202940
Created by
admin on Sat Dec 16 07:27:57 GMT 2023 , Edited by admin on Sat Dec 16 07:27:57 GMT 2023
|
PRIMARY | |||
|
118353-05-2
Created by
admin on Sat Dec 16 07:27:57 GMT 2023 , Edited by admin on Sat Dec 16 07:27:57 GMT 2023
|
PRIMARY | |||
|
DTXSID00869614
Created by
admin on Sat Dec 16 07:27:57 GMT 2023 , Edited by admin on Sat Dec 16 07:27:57 GMT 2023
|
PRIMARY | |||
|
135433604
Created by
admin on Sat Dec 16 07:27:57 GMT 2023 , Edited by admin on Sat Dec 16 07:27:57 GMT 2023
|
PRIMARY | |||
|
614846
Created by
admin on Sat Dec 16 07:27:57 GMT 2023 , Edited by admin on Sat Dec 16 07:27:57 GMT 2023
|
PRIMARY | |||
|
421843
Created by
admin on Sat Dec 16 07:27:57 GMT 2023 , Edited by admin on Sat Dec 16 07:27:57 GMT 2023
|
PRIMARY | |||
|
05469V2RW8
Created by
admin on Sat Dec 16 07:27:57 GMT 2023 , Edited by admin on Sat Dec 16 07:27:57 GMT 2023
|
PRIMARY | |||
|
C1039
Created by
admin on Sat Dec 16 07:27:57 GMT 2023 , Edited by admin on Sat Dec 16 07:27:57 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
